antibodi
crucial
part
immun
respons
invad
virus
induct
neutral
antibodi
primari
goal
vaccin
addit
great
interest
isol
engin
broadli
neutral
antibodi
major
human
pathogen
human
immunodefici
viru
influenza
viru
prophylact
therapeut
use
antibodymedi
neutral
gener
consid
occur
extracellularli
due
exclus
antibodi
cell
interior
membran
compartment
extracellular
neutral
also
report
potenti
engag
fc
receptor
howev
identif
tripartit
motif
high
affin
cytosol
antibodi
receptor
antivir
function
extend
understand
reach
antibodi
immun
includ
cytosol
cell
extracellular
viral
neutral
thought
requir
given
level
antibodi
occup
specif
epitop
prevent
entri
cell
howev
virus
known
display
immunodomin
epitop
bia
polyclon
antibodi
respons
toward
nonentri
neutral
epitop
impli
virus
bacteria
capac
penetr
cell
membran
enter
cytosol
compart
even
opson
antibodi
opportunist
pathogen
rapidli
sens
cytosol
induc
synchron
effector
signal
respons
antibodyopson
nonenvelop
virus
rapidli
target
degrad
via
proteasom
induc
innat
immun
respons
bacteria
complex
antibodi
trigger
innat
immun
signal
possibl
kill
via
autophagi
case
function
link
intrins
cellular
selfdefens
system
adapt
immun
take
advantag
divers
antibodi
repertoir
detect
invad
distinguish
member
trim
protein
famili
antivir
function
gener
recogn
invad
pathogen
directli
recognit
also
distinct
innat
sensor
pattern
recognit
receptor
detect
pathogen
associ
molecular
pattern
pamp
instead
treat
displac
antibodi
extracellular
intracellular
environ
danger
associ
molecular
pattern
damp
viral
restrict
may
also
synerg
protect
antivir
mechan
mediat
complement
system
addit
role
intracellular
defens
implic
therapi
research
tool
cell
biolog
begin
emerg
includ
identif
key
player
prevent
effici
adenoviru
base
gene
deliveri
vaccin
well
proteasom
target
spread
tau
protein
latter
promot
tau
degrad
instead
intracellular
aggreg
associ
sever
neurodegen
diseas
final
microinject
transform
antibodi
cell
use
direct
intracellular
protein
mediat
destruct
technolog
call
trimaway
use
studi
protein
function
cell
function
summar
figur
review
discuss
current
understand
cytosol
fc
receptor
execut
effector
function
alon
synergi
complement
system
addit
highlight
consid
context
diseas
therapi
multidomain
protein
consist
ntermin
ring
domain
ubiquitin
ligas
activ
bbox
domain
coiledcoil
dimer
domain
ctermin
pryspri
domain
domain
architectur
conserv
within
trim
protein
famili
ctermin
pryspri
domain
contain
antibodi
bind
site
thu
dictat
function
pryspri
domain
globular
fold
compris
two
antiparallel
connect
flexibl
loop
subdivid
pri
spri
element
solut
exist
homodim
form
stabl
complex
antibodi
two
pryspri
domain
bind
symmetr
fc
illustr
dimer
complex
antibodi
shown
figur
also
known
first
identifi
major
autoantigen
autoimmun
diseas
sjogren
syndrom
system
lupu
erythematosu
sle
autoantibodi
gener
sle
specif
ring
bbox
domain
fc
bind
pryspri
domain
interact
part
immunoglobulin
heavi
chain
first
report
fals
posit
yeast
twohybrid
screen
sinc
direct
bind
bona
fide
antibodi
demonstr
affin
mechan
bind
dissect
sitedirect
mutagenesi
bind
studi
combin
solv
crystal
structur
human
pryspri
domain
complex
human
fc
fragment
structur
confirm
two
pryspri
domain
bind
side
homodimer
fc
bind
site
locat
c
h
h
interfac
fc
distal
bind
site
classic
receptor
complement
factor
overlap
neonat
fc
receptor
fcrn
well
viral
bacteri
defens
protein
figur
notabl
interact
larg
phindepend
unaffect
remov
biantennari
nglycan
structur
attach
fc
c
h
domain
howev
sensit
high
salt
concentr
core
interact
form
protrud
loop
encompass
residu
fc
c
h
domain
deep
bind
pocket
form
surfac
pryspri
domain
apex
residu
hnhymotif
fc
loop
insert
pryspri
bind
pocket
residu
form
hydrogen
bond
network
base
pocket
protect
solvent
shield
hydrophob
side
chain
key
interact
residu
pryspri
domain
includ
detail
view
interact
depict
figur
bind
affin
human
recombin
human
pryspri
domain
measur
rang
nm
isotherm
titrat
calorimetri
surfac
plasmon
reson
howev
sinc
homodimer
function
affin
upon
bind
symmetr
fc
low
nm
measur
fluoresc
anisotropi
repres
increas
compar
monomer
bind
make
highest
affin
fc
receptor
known
human
interact
highli
conserv
across
speci
illustr
fact
human
mous
effici
bind
igg
rang
mammal
also
strict
correl
site
specif
mutat
made
mous
bind
mous
human
igg
subclass
indic
thermodynam
kinet
bind
conserv
across
speci
line
distinguish
fc
receptor
pryspri
domain
bind
four
igg
subclass
also
igm
iga
monomer
affin
pryspri
igm
iga
much
weaker
respect
due
larg
differ
amino
acid
composit
fc
loop
correspond
hnhymotif
igg
pnrv
igm
plaf
iga
howev
loop
accommod
pryspri
bind
pocket
due
dimer
natur
fulllength
function
affin
like
rang
igm
iga
shown
trigger
effector
function
whether
abl
interact
igd
ige
yet
investig
nevertheless
known
fc
receptor
capabl
interact
three
distinct
antibodi
isotyp
respond
antibodyco
virus
cytosol
studi
detail
use
human
adenoviru
type
model
pathogen
upon
infect
cell
complex
mediat
sequenti
coordin
effector
signal
respons
involv
proteasom
degrad
viru
induct
antivir
cellular
state
activ
innat
immun
signal
pathway
degrad
invad
virus
term
antibodi
depend
intracellular
neutral
adin
process
occur
rapid
kinet
observ
antibodi
per
viru
dual
effector
respons
fulli
depend
ubiquitin
ligas
activ
mediat
ring
domain
upon
engag
antibodi
ntermin
monoubiquitin
enzym
monoubiquitin
act
primer
ubiquitin
chain
extens
via
linkag
use
enzym
complex
deplet
cellular
lead
loss
ubiquitin
overexpress
suggest
subsequ
ubiquitin
may
incorpor
form
mix
branch
chain
autoubiquitin
ultim
target
antibodi
antigen
complex
proteasom
degrad
proteasom
associ
deubiquitinas
liber
ubiquitin
chain
en
bloc
induc
irf
signal
pathway
via
tabtak
nemo
result
product
proinflammatori
cytokin
atpas
protein
vcp
enzym
segregas
unfoldas
activ
need
degrad
viral
particl
possibl
intact
capsid
disassembl
individu
compon
degrad
proteasom
viru
degrad
expos
viral
genom
cytosol
dna
rna
sensor
cga
initi
second
wave
immun
signal
respons
human
rhinoviru
infect
respect
dual
effector
function
outlin
figur
contribut
system
protect
vivo
demonstr
mouseadenoviru
type
infect
mice
mice
passiv
transfus
specif
antiserum
experi
activ
prevent
induc
hemorrhag
enceph
mice
lack
higher
viral
load
increas
mortal
compar
wildtyp
wt
anim
mice
heterozyg
display
intermedi
phenotyp
interestingli
fact
naiv
mice
demonstr
depend
protect
suggest
earli
antibodi
respons
like
form
igm
work
vivo
prevent
infect
also
use
fulli
replic
demonstr
effect
activ
spread
infect
togeth
experi
show
make
substanti
contribut
system
protect
import
part
humor
immun
respons
recent
role
immun
activ
map
detail
genomewid
differenti
gene
express
analysi
use
rnaseq
analysi
reveal
immun
signal
strictli
depend
bind
antibodi
knockout
ko
mice
gene
express
infect
anim
bare
affect
similarli
infect
presenc
hexon
specif
mousehuman
chimer
antibodi
result
differenti
express
gene
wt
ko
mice
furthermor
infect
presenc
engin
version
nonbind
result
similar
gene
express
pattern
infect
alon
thu
genet
knockdown
abrog
interact
protein
level
prevent
immun
activ
importantli
mutat
specif
ablat
bind
without
impair
bind
fc
receptor
affect
serum
halflif
antibodi
within
timefram
experi
specif
contribut
immun
signal
determin
compar
transcript
chang
immun
gene
induc
upon
infect
wt
vs
ko
mice
use
vs
specif
induc
gene
relat
innat
intrins
immun
oppos
gene
associ
strong
inflammatori
respons
acut
phase
protein
indic
potent
posit
immun
regul
focus
antivir
respons
toward
intrins
immun
extracellular
engag
classic
transmembranebound
fc
receptor
result
intracellular
activ
inhibitori
signal
transduct
regul
depend
upon
factor
express
level
receptor
crosslink
ratio
activ
inhibitori
receptor
togeth
set
activ
threshold
likewis
innat
immun
respons
insid
cell
must
also
tightli
control
member
trim
protein
famili
sens
ligand
enter
cytosol
wellunderstood
trigger
signal
one
regulatori
mechan
propos
trim
protein
activ
higher
order
assembl
base
earli
observ
format
socal
cytoplasm
bodi
requir
higher
order
assembl
drive
ubiquitin
activ
first
suggest
assembl
thought
requir
allow
ring
domain
dimer
normal
separ
trim
dimer
long
coiledcoil
drive
trim
assembl
less
clear
engag
retrovir
capsid
induc
oligomer
hexagon
assembl
via
bbox
interact
multipl
molecul
mutat
disrupt
dimer
inhibit
catalyt
activ
ring
dimer
requir
enzym
bind
need
form
contact
ubiquitin
demonstr
mutat
ring
dimer
interfac
disrupt
catalyt
activ
vitro
likewis
higher
order
assembl
drive
ntermin
ubiquitin
requir
activ
capsid
disassembl
furthermor
overexpress
cell
constitut
induc
activ
absenc
infect
like
due
spontan
format
cytoplasm
bodi
turn
drive
autoubiquitin
result
rapid
protein
turnov
proteasom
target
howev
activ
strategi
seem
use
sinc
bbox
autoinhibitori
overexpress
cell
activ
proteasom
degrad
occur
absenc
viru
antibodi
moreov
substitut
correspond
residu
crucial
dimer
render
catalyt
inact
differ
observ
despit
fact
isol
ring
domain
highli
catalyt
activ
vitro
activ
regul
recent
result
reveal
autoregul
via
bbox
domain
delet
bbox
increas
catalyt
activ
ring
domain
repres
novel
function
bbox
domain
structur
explain
fact
bbox
mimic
occupi
ubiquitin
ligas
bind
site
ring
domain
therebi
prevent
autoubiquitin
activ
immun
signal
reveal
solv
crystal
structur
truncat
form
contain
ring
bbox
domain
structur
observ
confirm
nuclear
magnet
reson
nmr
enzym
bound
ring
ringbbox
variant
thu
respond
antibodi
bound
viru
cytosol
mechan
reliv
inhibitori
effect
bbox
must
place
autoinhibitori
mechan
shown
releas
phosphoryl
nonconserv
serin
residu
posit
human
ring
domain
kinas
drive
bbox
displac
ring
line
stimul
cell
poli
c
infect
antibodi
coat
result
phosphoryl
part
plxsi
like
motif
ctermin
end
ring
domain
locat
bind
interfac
bbox
phosphomimick
mutat
introduc
ringbbox
variant
catalyt
activ
restor
cellular
data
support
role
phosphoryl
infect
antibodybound
cell
express
mutant
activ
activ
cytokin
product
restor
cell
express
variant
direct
evid
bbox
displac
bind
obtain
nmr
use
variant
interestingli
similar
regulatori
mechan
exist
unrel
innat
immun
adaptor
mitochondri
antivir
signal
protein
mav
stimul
interferon
gene
sting
tirdomaincontain
adapterinduc
trif
signal
potenti
serin
phosphoryl
similar
plxsi
motif
strikingli
depend
neutral
proce
independ
phosphoryl
state
suggest
signal
higher
activ
threshold
neutral
import
observ
sinc
neutral
signal
arm
requir
ubiquitin
suggest
neutral
proceed
basal
level
without
innat
signal
trigger
find
consist
earlier
studi
show
neutral
effici
use
engin
variant
reduc
bind
induct
ablat
sever
diminish
furthermor
design
variant
differ
onand
offrat
kinet
demonstr
slower
rate
gener
correl
effici
activ
signal
function
abrog
faster
reduct
rate
compar
neutral
function
may
allow
low
level
activ
without
induc
antivir
state
might
import
clear
low
level
free
antibodi
displac
cytosol
import
question
remain
answer
role
effector
function
play
differ
cell
type
recent
complex
fcengin
variant
improv
bind
pryspri
domain
report
upregul
costimulatori
molecul
hladr
well
increas
product
proinflammatori
cytokin
monocyt
deriv
dendrit
cell
translat
enhanc
crossprim
activ
cell
high
multipl
infect
contrast
adin
activ
found
unaffect
although
exact
intracellular
mechan
respons
cell
crossprim
remain
determin
data
suggest
artifici
antibodi
bound
adenoviru
increas
abil
dendrit
cell
activ
cell
highlight
use
fcengin
taken
togeth
although
effector
signal
function
synchron
respond
distinct
separ
manner
antibodi
engag
antigen
bind
autoubiquitin
stringent
requir
activ
immun
signal
compar
neutral
serv
preserv
import
hallmark
immun
elicit
balanc
proportion
respons
regul
fail
consequ
constitut
activ
would
like
trigger
chronic
inflamm
demonstr
lysosomematur
impair
macrophag
lupuspron
mice
leakag
igg
contain
immun
complex
endosom
pathway
cytosol
trigger
depend
inflammatori
respons
absenc
infect
antivir
function
studi
use
sever
virus
includ
human
rhinoviru
addit
shown
porcin
abl
restrict
foot
mouth
diseas
viru
requir
activ
entri
antibodyco
particl
cytosol
believ
envelop
virus
target
receptor
sinc
leav
membran
along
bound
antibodi
cell
surfac
upon
fusion
plasma
membran
demonstr
human
respiratori
syncyti
viru
rsv
bound
therapeut
monoclon
antibodi
palivizumab
synagi
r
nonenvelop
virus
form
pore
endosom
membran
genom
inject
capsid
attach
antibodi
sens
paratop
antibodi
well
epitop
viru
may
also
determin
whether
target
case
studi
viru
context
capsid
fiber
protein
shed
endocytosi
via
integrin
coxsacki
adenoviru
receptor
car
follow
rest
viral
particl
cytosol
therefor
monoclon
fiber
specif
antibodi
poorli
recruit
howev
antibodi
polyclon
sera
entri
block
target
epitop
immunodomin
major
capsid
protein
hexon
interestingli
sens
limit
viral
infect
signal
may
also
trigger
respons
antibodyco
bacteria
salmonella
enterica
addit
nonpathogen
complex
hostderiv
protein
bound
antibodi
antibodyco
bead
also
target
activ
dual
effector
function
adenovirus
major
target
gene
therapi
object
deliv
gene
variant
gene
encod
vaccin
epitop
express
host
target
cell
adenovirus
particular
frequent
use
vehicl
transgen
howev
sinc
adenovirus
common
pathogen
human
preexist
antibodi
immun
viru
sever
limit
use
often
prevent
express
transgen
notabl
normal
human
serum
may
contain
much
specif
igg
thu
base
gene
deliveri
vehicl
coat
antibodi
intraven
inject
iv
may
explain
tcell
respons
deliv
vaccin
antigen
poorli
induc
howev
find
biolog
explan
presenc
antibodi
block
gene
express
puzzl
prevent
deliveri
transgen
cytoplasm
space
recent
substanti
proport
antibodi
inhibit
demonstr
mediat
naiv
mice
infect
carri
luciferas
encod
transgen
presenc
antibodi
express
transgen
liver
reduc
compar
viru
administ
alon
transgen
express
affect
antibodi
ko
mice
wt
mice
use
nonbind
mutant
depend
block
transgen
express
also
observ
use
polyclon
mous
serum
rais
notabl
potenti
rerout
viru
via
classic
mediat
uptak
signific
import
infect
presenc
variant
bind
affect
block
transgen
express
impair
tcell
respons
siinfekl
epitop
ovalbumin
ova
demonstr
depend
mice
vaccin
carri
ova
transgen
presenc
antibodi
result
reduc
antivir
immun
establish
use
engin
influenza
viru
strain
carri
peptid
neuramidas
stalk
well
reduc
antitumor
immun
shown
challeng
adova
immun
anim
ova
secret
fibrosarcoma
cell
line
addit
block
transgen
express
induct
unwant
innat
immun
signal
may
occur
upon
administr
adenoviru
base
gene
deliveri
vector
may
relat
activ
preclin
support
studi
mice
infect
presenc
amplifi
transcript
level
proinflammatori
induc
cytokin
ifn
ifn
stimul
gene
isg
measur
liver
respons
compar
cpg
indic
biolog
relev
induct
level
clinic
gene
therapi
trial
indic
preexist
immun
vector
circumv
intramuscular
intranas
deliveri
vector
given
intranas
block
ova
transgen
deliveri
potent
seen
iv
deliveri
howev
accompani
weaker
ovaspecif
tcell
respons
insight
blockad
transgen
express
deliv
adenoviru
vector
mediat
open
develop
strategi
circumv
target
gene
therapi
vector
given
reduc
tcell
respons
associ
altern
deliveri
rout
vector
shield
strategi
avoid
preexist
immun
may
advantag
approach
neg
impact
gene
therapi
activ
receptor
may
favor
util
therapeut
applic
one
interest
area
neurodegen
disord
alzheim
diseas
character
aggreg
intracellular
microtubuleassoci
tau
protein
intracellular
tau
aggreg
gener
extracellular
tau
spread
cell
administr
tau
specif
antibodi
known
reduc
tau
induc
patholog
mice
underli
mechan
elucid
yet
interestingli
shown
inhibit
intracellular
tau
aggreg
newli
establish
vitro
tau
seed
assay
recapitul
tau
aggreg
diseas
brain
intercept
extracellular
tau
antitau
antibodi
extracellular
environ
celltocel
transfer
result
depend
proteasom
degrad
tau
aggreg
fast
cytoplasm
entri
rapid
recruit
incom
antibodi
tau
complex
like
crucial
prevent
discoveri
may
foster
develop
new
therapeut
approach
deliveri
strategi
antibodi
bloodbrain
barrier
could
combin
target
extracellular
tau
abil
target
cytosol
protein
tag
antibodi
degrad
util
research
recent
demonstr
technolog
coin
trimaway
method
reli
introduc
antibodi
specif
intracellular
protein
interest
singl
cell
microinject
cell
cultur
electropor
principl
exemplifi
microinject
antigfp
antibodi
human
cell
line
nih
overexpress
free
gfp
led
degrad
gfp
within
minut
likewis
gfp
fuse
lipid
endogen
protein
local
distinct
place
within
primari
mous
oocyt
plasma
membran
endosom
membran
nucleu
gfp
effici
target
deplet
nuclear
protein
depend
upon
antibodi
access
nucleu
nondivid
cell
take
place
one
approach
solv
problem
use
altern
smaller
antibodi
format
instanc
fc
fragment
fuse
antigfp
nanobodi
facilit
effici
nuclear
transport
target
degrad
robust
method
studi
mous
oocyt
target
nuclear
protein
result
rapid
degrad
prevent
bipolar
mitot
spindl
format
yet
anoth
exampl
target
deplet
longliv
protein
mous
egg
led
separ
sister
chromatid
importantli
latter
exampl
address
major
challeng
name
longliv
protein
effect
deplet
use
standard
dna
rna
base
method
due
slow
turnov
rate
cell
final
trimaway
allow
deplet
specif
protein
primari
human
cell
demonstr
deplet
ikk
primari
human
macrophag
deplet
also
shown
function
alter
macrophag
make
resist
pyroptosi
reduc
releas
potent
inflammatori
cytokin
trimaway
use
demonstr
involv
meiotic
arrest
regul
exocytosi
develop
mous
egg
use
trimaway
manipul
primari
cell
highlight
fact
approach
transfect
transduct
rna
dna
ineffici
stimul
innat
signal
durat
knockdown
trimaway
correl
amount
antibodi
present
satur
cell
expos
high
viral
load
complex
antibodi
explain
express
level
also
part
fact
degrad
togeth
antibodi
bound
target
despit
ifninduc
like
crucial
sustain
activ
ongo
infect
express
level
mani
case
limit
factor
trimaway
strategi
especi
true
abund
cellular
protein
target
overcom
overexpress
coadministr
recombin
microinject
electropor
importantli
overexpress
alter
cellular
transcriptom
cell
phenotyp
endogen
level
propos
ligand
centrosom
protein
percentrin
target
nih
cell
overexpress
effici
deplet
percentrin
fail
local
nuclear
interact
partner
addit
method
use
either
activ
inhibit
signal
transduct
pathway
target
differ
compon
recent
trimaway
method
also
report
attract
tool
degrad
delay
express
protein
zebrafish
embryo
thu
enabl
investig
specif
protein
affect
embryon
development
process
major
advantag
trimaway
rapid
allow
monitor
phenotyp
chang
cell
time
limit
appear
compensatori
mechan
hand
reli
use
antibodi
highli
specif
crossreact
intracellular
protein
potenti
issu
taken
consider
possibl
target
one
cellular
protein
may
result
concomit
deplet
strong
interact
partner
howev
knockon
effect
also
like
result
reduc
express
target
via
sirna
shrna
gene
ko
via
crispr
immun
system
orchestr
rang
effector
mechan
protect
infect
human
complement
system
consist
protein
label
pathogen
destruct
via
classic
mannos
lectin
altern
pathway
label
virus
may
still
enter
endosom
compart
well
cytosol
complement
may
synerg
differ
way
prevent
cellular
infect
nonenvelop
virus
mechan
illustr
figur
first
demonstr
deposit
viru
surfac
via
altern
complement
pathway
factor
b
depend
manner
deposit
trigger
dual
effector
respons
similar
mediat
cytosol
coat
target
proteasom
vcp
depend
manner
degrad
also
induc
innat
signal
via
irf
nonhematopoiet
cell
mediat
immun
activ
may
synerg
antibodi
depend
signal
efficaci
signal
vari
among
differ
virus
polioviru
strength
respons
correl
degre
endosom
lysi
escap
intact
bound
capsid
cytosol
envelop
virus
rsv
effici
trigger
cytosol
effector
respons
intracellular
receptor
yet
identifi
like
involv
ifn
induc
gene
depend
neutral
potenti
ifn
stimul
signal
respons
depend
mav
proce
tnf
receptorassoci
traf
pathway
mav
requir
depend
neutral
suggest
initi
sens
occur
via
upstream
compon
antagonist
mechan
identifi
certain
virus
hrv
produc
cytosol
proteas
cleav
protect
mechan
demonstr
proteas
disabl
signal
degrad
cytosol
nonhematopoiet
cell
phenotyp
could
revers
proteas
inhibitor
rupintrivir
fact
use
antibodi
sens
pathogen
oppos
direct
deposit
suggest
difficult
viru
directli
antagon
hand
nonenvelop
virus
inject
viral
genom
cytosol
via
pore
form
endosom
membran
separ
antibodi
consid
viral
protect
strategi
addit
direct
deposit
viral
capsid
via
altern
pathway
antibodi
opson
pathogen
may
recruit
complex
initi
classic
complement
pathway
recruit
result
cleavag
follow
associ
form
convertas
cleav
lead
opson
downstream
format
membran
attack
complex
mac
recent
neutral
shown
occur
via
axi
also
via
classic
complement
pathway
neutral
mechan
depend
bind
antibodyopson
subsequ
deposit
viru
occur
independ
complement
compon
infect
stepwis
process
progress
bind
host
cell
receptor
endocytosi
lysi
endosom
membran
engag
two
host
cell
receptor
car
integrin
bind
event
provid
mechan
cue
viru
commenc
stepwis
uncoat
process
result
loss
fiber
protein
exposur
membran
lytic
protein
vi
lyse
endosom
membran
upon
entri
cytosol
hexon
recruit
dynein
capsid
move
toward
nucleu
process
capsid
continu
progress
disassembl
metast
state
ultim
serv
deliv
viral
genom
nucleu
howev
deposit
antibodi
coat
viru
interfer
viral
disassembl
endosom
sinc
membran
lytic
protein
vi
expos
consequ
viru
rout
endolysosom
pathway
reach
cytosol
experi
opson
mutant
variant
fail
interact
viru
readili
escap
cytosol
instead
target
thu
like
figur
synerg
complement
system
deposit
enter
cell
via
car
mediat
endocytosi
upon
complex
escap
cytosol
detect
may
occur
synergist
engag
case
direct
proteasom
degrad
follow
ubiquitin
mav
mediat
induct
irf
antibodi
coat
bound
may
result
deposit
prior
endocytosi
via
car
integrin
prevent
exposur
membran
lytic
protein
vi
block
endosom
escap
instead
rout
lysosom
degrad
figur
made
use
biorend
tm
depend
neutral
pathway
may
oper
synergist
infect
rais
question
neutral
mechan
domin
differ
condit
deposit
surfac
extent
result
depend
neutral
roughli
antibodi
must
bind
viru
ec
deposit
determin
lower
normal
serum
concentr
specif
igg
titer
around
normal
human
serum
strongli
indic
mediat
neutral
like
significantli
contribut
factor
vivo
confirm
mice
infect
express
luciferas
transgen
express
transgen
inhibit
presenc
partial
restor
ko
mice
remain
block
transgen
express
depend
consist
observ
vitro
ko
mice
given
presenc
transgen
express
fulli
restor
control
level
effect
confirm
wt
mice
vaccin
togeth
doubl
neg
mutant
bind
tcell
induct
complet
restor
day
post
administr
thu
complement
system
may
work
concert
prevent
infect
also
block
base
gene
deliveri
insight
preexist
antibodi
limit
efficaci
gene
therapi
may
pave
way
strategi
circumv
problem
one
conceiv
strategi
may
precoat
vector
antibodi
engin
ignor
simpli
use
fab
fragment
use
vitro
competit
assay
infect
measur
presenc
constant
amount
increasingli
higher
concentr
fab
strategi
shown
interfer
complement
mediat
neutral
low
concentr
contrast
much
higher
concentr
competitor
requir
prevent
mediat
neutral
reflect
neutral
requir
antibodi
bound
viru
effect
effici
neutral
requir
higher
antibodi
coat
level
wt
mice
infect
carri
luciferas
transgen
presenc
excess
deriv
fab
fragment
improv
transgen
express
observ
importantli
fab
precoat
strategi
also
diminish
polyclon
antibodi
respons
toward
vector
administ
intramuscularli
mice
suggest
strategi
could
also
prevent
protect
antibodi
respons
repeat
vector
dose
hexon
primari
immunogen
antibodi
gener
bind
apex
hexon
trimer
spike
may
particularli
well
suit
precoat
inde
shield
surfac
trival
scfv
high
avid
use
combin
target
design
ankyrin
repeat
protein
darpin
bind
fiber
knob
vector
darpin
unit
block
car
mediat
uptak
retarget
vector
egfr
posit
tumor
cell
mice
combin
strategi
improv
tumor
liver
local
ratio
vector
circumv
intracellular
neutral
thu
significantli
boost
transgen
express
role
high
affin
cytosol
fc
receptor
grown
signific
diseas
therapi
use
genet
ko
vitro
mice
togeth
specif
ko
interact
protein
level
use
engin
antibodi
variant
solidifi
role
posit
immun
regul
whose
activ
strictli
depend
detect
cytosol
antibodyviru
complex
note
howev
also
implic
posit
neg
regul
innat
signal
independ
antibodi
bind
furthermor
identif
major
player
antibodi
mediat
block
gene
therapi
togeth
effect
complement
factor
inspir
strategi
shield
gene
deliveri
vector
preexist
immun
find
shield
strategi
limit
immun
respons
vector
particular
interest
case
repeat
administr
need
moreov
remark
abil
engag
three
differ
antibodi
isotyp
sharp
contrast
fc
receptor
highli
select
regard
isotyp
subclass
bind
properti
earli
primari
immun
respons
infect
domin
igm
igg
emerg
later
secondari
respons
upon
reinfect
igg
respons
initi
follow
consid
antivir
subclass
howev
four
human
igg
subclass
activ
cytosol
bound
virus
yet
address
detail
furthermor
sinc
may
synerg
complement
system
import
fulli
understand
antivir
immun
orchestr
differ
antibodi
isotyp
subclass
absenc
presenc
even
though
circumvent
util
activ
therapeut
purpos
concept
stage
impact
allevi
block
adenoviru
base
gene
therapi
use
antibodi
prevent
intracellular
tau
aggreg
potenti
huge
method
deliv
antibodi
cytosol
specif
cell
vivo
suffici
efficaci
develop
one
could
even
imagin
trimaway
technolog
could
exploit
therapeut
specif
degrad
intracellular
diseas
associ
protein
furthermor
function
extens
studi
use
model
pathogen
adenoviru
infect
healthi
individu
gener
benign
may
caus
sever
complic
even
death
immunocompromis
immunosuppress
patient
exampl
aggress
adenoviru
infect
human
eye
known
epiderm
keratoconjunct
may
lead
loss
vision
avail
treatment
option
whether
adenoviru
infect
eye
may
benefit
antibodi
therapi
remain
address
howev
inject
antibodi
vitreou
frequent
use
clinic
treat
eye
diseas
agerel
macular
edema
activ
strong
inflammatori
respons
may
benefici
treatment
set
use
engin
antibodi
reduc
affin
alter
antigen
bind
kinet
could
attract
reduc
inflamm
without
compromis
viru
neutral
abil
take
advantag
antibodi
repertoir
orchestr
potent
intracellular
immun
respons
invad
pathogen
provid
nonhematopoiet
cell
mean
activ
protect
even
viru
enter
cytosol
howev
also
express
profession
immun
cell
role
cell
type
affect
antigen
process
present
context
antibodi
bind
receptor
import
address
